August 5, 2024 07:28 AM EDT

Bayer plans label expansion for Kerendia after Phase 3 win in heart failure

Katherine Lewin

News Reporter

Bayer touted a win in a Phase 3 heart failure study with Kerendia on Monday, announcing that the drug hit the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

view job offer post your job now

TRENDING NOW

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Lack of detail in Trump's drug price plan raises more questions than answers

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees